Title
Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial
Date Issued
01 May 2022
Access level
metadata only access
Resource Type
journal article
Author(s)
Gnanamanogaran B.
Al-Ozzi T.M.
Cohn M.
Tomlinson G.
Boutet A.
Elias G.J.B.
Germann J.
Soh D.
Kalia S.K.
Hodaie M.
Munhoz R.P.
Marras C.
Hutchison W.D.
Lozano A.M.
Lang A.E.
Fasano A.
University of Toronto, University of Rochester
Publisher(s)
John Wiley and Sons Inc
Abstract
Background: Patients with Parkinson's disease might develop treatment-resistant axial dysfunction after bilateral subthalamic stimulation. Objectives: To study whether lateralized stimulation (unilateral 50% amplitude reduction) for ≥21 days results in ≥0.13 m/s faster gait velocity in the dopaminergic ON state in these patients, and its effects on motor and axial function, quantitative gait and speech measures, quality of life, and selected cognitive tasks. Methods: Randomized, double-blinded, double-crossover trial. Results: In 22 participants (51–79 years old, 15 women), there were no significant changes in gait velocity, quality of life, cognitive, and speech measures. Reducing left-sided amplitude resulted in a 2.5-point improvement in axial motor Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (P = 0.005, uncorrected) and a 1.9-point improvement in the Freezing of Gait Questionnaire (P = 0.024, uncorrected). Conclusions: Lateralized subthalamic stimulation does not result in meaningful improvement in gait velocity in patients with Parkinson's disease who develop treatment-resistant axial dysfunction after bilateral subthalamic stimulation. Left subthalamic overstimulation may contribute to axial deterioration in these patients. © 2022 International Parkinson and Movement Disorder Society.
Start page
1079
End page
1087
Volume
37
Issue
5
Language
English
OCDE Knowledge area
Neurociencias
Subjects
Scopus EID
2-s2.0-85124507759
PubMed ID
Source
Movement Disorders
ISSN of the container
0885-3185
Sponsor(s)
The authors thank Pratika Bandari and Eleonora Galletti for their assistance during cognitive assessments. The authors thank Drs. Sreeram Prasad, Musleh Algarni, Vijayashankar Paramanandam, and Lais Machado de Oliveira for the care provided to study participants. Part of the study design was developed during the 2017 Clinical Trials Methodology Course sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) (NIH R25:NS088248). K.J.L. is thankful for the feedback received on this study during the 2019-2021 program Training in Research for Academic Neurologists to Sustain Careers and Enhance the Numbers of Diverse Scholars (TRANSCENDS) sponsored by the NINDS (NIH R25:NS098999).
K.J.L.: Research support from Abbvie, Acadia, Genentech, and the National Institutes of Health. Educational funding from Medtronic. S.K.K.: consultant for Medtronic. C.M.: Research support from The Michael J. Fox Foundation, Canadian Institutes of Health Research, Centogene, International Parkinson and Movement Disorders Society, Theravance, and as site investigator for STEADY‐PD III study. Consultant for Grey Matter Technologies. Honoraria from The Michael J. Fox Foundation and Parkinson's Foundation. W.D.H.: Consultant for Medtronic. A.M.L.: Consultant for Abbott, Boston Scientific, Medtronic, Functional Neuromodulation. Co‐founder of Functional Neuromodulation Ltd. A.E.L.: Consultant for Abbvie, Acorda, AFFiRiS, Biogen, Denali, Janssen, Intracellular, Kallyope, Lundbeck, Paladin, Retrophin, Roche, Sun Pharma, Theravance, Corticobasal Degeneration Solutions. Honoraria from Sun Pharma, Abbvie, Sunovion, American Academy of Neurology, International Parkinson and Movement Disorder Society. Royalties from Elsevier, Saunders, Wiley‐Blackwell, Johns Hopkins Press, Cambridge University Press. Grants from Brain Canada, Canadian Institutes of Health Research, Corticobasal Degeneration Solutions, Edmond J. Safra Philanthropic Foundation, The Michael J. Fox Foundation, Ontario Brain Institute, Parkinson Foundation, Parkinson Canada, W. Garfield Weston Foundation. A.F.: Honoraria from Abbott, Boston Scientific, Brainlab, Medtronic, Ceregate, UCB Pharma.
Sources of information:
Directorio de Producción Científica
Scopus